343 related articles for article (PubMed ID: 22588246)
21. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.
Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W
Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745
[TBL] [Abstract][Full Text] [Related]
22. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
23. Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.
Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; de Mendoza C; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
Antivir Ther; 2007; 12(4):459-68. PubMed ID: 17668554
[TBL] [Abstract][Full Text] [Related]
24. 1(OH) vitamin D3 supplementation improves the sensitivity of the immune-response during Peg-IFN/RBV therapy in chronic hepatitis C patients-case controlled trial.
Kondo Y; Kato T; Kimura O; Iwata T; Ninomiya M; Kakazu E; Miura M; Akahane T; Miyazaki Y; Kobayashi T; Ishii M; Kisara N; Sasaki K; Nakayama H; Igarashi T; Obara N; Ueno Y; Morosawa T; Shimosegawa T
PLoS One; 2013; 8(5):e63672. PubMed ID: 23717463
[TBL] [Abstract][Full Text] [Related]
25. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
[TBL] [Abstract][Full Text] [Related]
27. [Discussion on optimal duration of pegylated interferon α combined with ribavirin for chronic hepatitis C in HIV-infected patients].
Ke YC; Li LH; Hu FY; Lan Y; He YZ; Chen XJ; Tang XP; Cai WP; Lu RC; He Y; Li HQ
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):282-287. PubMed ID: 29996340
[No Abstract] [Full Text] [Related]
28. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
29. Real life experience in treatment of HIV-1/HCV-coinfected patients with pegylated interferon alpha and ribavirin: predictors of SVR.
Bruno G; Fasano M; Saracino A; Volpe A; Bartolomeo N; Ladisa N; Maggi P; Monno L; Angarano G
New Microbiol; 2015 Jan; 38(1):21-7. PubMed ID: 25742144
[TBL] [Abstract][Full Text] [Related]
30. Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Neukam K; Barreiro P; Rivero-Juárez A; Caruz A; Mira JA; Camacho A; Macías J; Rivero A; Soriano V; Pineda JA
J Infect; 2013 Jul; 67(1):59-64. PubMed ID: 23542783
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
[TBL] [Abstract][Full Text] [Related]
32. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients.
Marchetti G; Nasta P; Bai F; Gatti F; Bellistrì GM; Tincati C; Borghi F; Carosi G; Puoti M; Monforte Ad
PLoS One; 2012; 7(2):e32028. PubMed ID: 22363790
[TBL] [Abstract][Full Text] [Related]
33. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
[TBL] [Abstract][Full Text] [Related]
34. Impact of hepatitis B virus integration into liver tissue on the efficacy of peginterferon and ribavirin therapy in hepatitis B virus-negative chronic hepatitis C patients.
Toyoda H; Kumada T; Tada T; Murakami Y
J Clin Gastroenterol; 2014 Jan; 48(1):73-9. PubMed ID: 23842217
[TBL] [Abstract][Full Text] [Related]
35. Ribavirin and IFN-alpha combination therapy induces CD4+ T-cell proliferation and Th1 cytokine secretion in patients with chronic hepatitis B.
Ren FY; Jin H; Piao XX; Piao FS
World J Gastroenterol; 2007 Nov; 13(41):5440-5. PubMed ID: 17907286
[TBL] [Abstract][Full Text] [Related]
36. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
[TBL] [Abstract][Full Text] [Related]
37. The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV.
Slim J; Mildvan D; Han J; Korner E
J Int Assoc Provid AIDS Care; 2013; 12(5):354-62. PubMed ID: 23873217
[TBL] [Abstract][Full Text] [Related]
38. [Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients].
Almeida PR; Tovo CV; Rigo JO; Zanin P; Alves AV; Mattos AA
Arq Gastroenterol; 2009; 46(2):132-7. PubMed ID: 19578615
[TBL] [Abstract][Full Text] [Related]
39. Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C.
Uyanikoglu A; Akyuz F; Baran B; Simsek BP; Ermis F; Demir K; Gulluoglu M; Badur S; Kaymakoglu S
Clin Res Hepatol Gastroenterol; 2013 Nov; 37(5):485-90. PubMed ID: 23665172
[TBL] [Abstract][Full Text] [Related]
40. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
